Vor Biopharma annual r&d spending
2020
2021
2022
2023
2024
2025
Vor Biopharma R&D Spending Growth & History (VOR)
Vor Biopharma's r&d spending was $321.5M for fiscal 2025.
View full Vor Biopharma company overviewVor Biopharma annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $321.5M | $228.2M | +244.58% |
| 2024 | 2024-12-31 | $93.3M | −$1.0M | −1.07% |
| 2023 | 2023-12-31 | $94.3M | $29.8M | +46.11% |
| 2022 | 2022-12-31 | $64.5M | $17.0M | +35.81% |
| 2021 | 2021-12-31 | $47.5M | $15.9M | +50.32% |
| 2020 | 2020-12-31 | $31.6M | — | — |
Vor Biopharma quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $25.9M | −$235.6M | −90.09% |
| Q1 2026 | 2026-03-31 | $17.6M | −$9.1M | −34.10% |
| Q4 2025 | 2025-12-31 | $19.2M | −$6.2M | −24.29% |
| Q3 2025 | 2025-09-30 | $14.1M | −$7.7M | −35.18% |
| Q2 2025 | 2025-06-30 | $261.5M | $239.7M | +1098.27% |
| Q1 2025 | 2025-03-31 | $26.7M | $2.4M | +9.78% |
| Q4 2024 | 2024-12-31 | $25.3M | $4.5M | +21.30% |
| Q3 2024 | 2024-09-30 | $21.8M | −$5.8M | −20.97% |
| Q2 2024 | 2024-06-30 | $21.8M | −$2.1M | −8.68% |
| Q1 2024 | 2024-03-31 | $24.3M | $2.4M | +10.98% |
| Q4 2023 | 2023-12-31 | $20.9M | $3.8M | +22.48% |
| Q3 2023 | 2023-09-30 | $27.6M | $10.7M | +63.59% |
| Q2 2023 | 2023-06-30 | $23.9M | $8.6M | +55.85% |
| Q1 2023 | 2023-03-31 | $21.9M | $6.6M | +43.42% |
| Q4 2022 | 2022-12-31 | $17.1M | $4.4M | +34.42% |
| Q3 2022 | 2022-09-30 | $16.9M | $4.0M | +30.56% |
| Q2 2022 | 2022-06-30 | $15.3M | $2.4M | +18.22% |
| Q1 2022 | 2022-03-31 | $15.3M | $6.3M | +70.90% |
| Q4 2021 | 2021-12-31 | $12.7M | $1.4M | +12.03% |
| Q3 2021 | 2021-09-30 | $12.9M | $4.8M | +58.74% |
| Q2 2021 | 2021-06-30 | $13.0M | $7.0M | +117.07% |
| Q1 2021 | 2021-03-31 | $8.9M | $2.8M | +44.89% |
| Q4 2020 | 2020-12-31 | $11.3M | — | — |
| Q3 2020 | 2020-09-30 | $8.1M | — | — |
| Q2 2020 | 2020-06-30 | $6.0M | — | — |
| Q1 2020 | 2020-03-31 | $6.2M | — | — |
Vor Biopharma r&d spending trends
Over the last five fiscal years, Vor Biopharma's r&d spending increased from $31.6M to $321.5M, a change of $289.9M. The latest reported quarter, Q2 2026, shows $25.9M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vor Biopharma source filings ↗